Philip Robinson discusses why TNF inhibitors may be a favorable treatment option for COVID-19 and outlines the trials that are currently underway (16:39).

Alfred Kim talks about the initial promise of hydroxychloroquine for COVID-19 and why it did not stand up to later scrutiny (13:06).

Alfred Kim talks about the initial promise of hydroxychloroquine for COVID-19 and why it did not stand up to later scrutiny (13:06).

Cristina Mussini discusses the current data on interleukin inhibitors for the treatment of COVID-19 and explores why tocilizumab has been associated with beneficial outcomes in some studies but not others (19:10).

Marwan Bukhari talks about the rationale behind investigating baricitinib and other JAK inhibitors for the treatment of COVID-19 and outlines the current efficacy data (10:42).

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

In the introductory podcast for our series on repurposing rheumatology drugs for COVID-19, Jinoos Yazdany discusses the rationale behind investigating these agents and explores the role of rheumatologists in ensuring they are studied as safely and efficiently as possible (13:07).

In the introductory podcast for our series on repurposing rheumatology drugs for COVID-19, Jinoos Yazdany discusses the rationale behind investigating these agents and explores the role of rheumatologists in ensuring they are studied as safely and efficiently as possible (13:07).

Click through for further information

Click through for further information on this announcement

Colchicine, an anti-inflammatory drug commonly used to treat gout and pericarditis, does not improve outcomes for people hospitalized with COVID-19, RECOVERY trial data show.

EULAR has updated its points to consider on the use of immunomodulatory therapies for the treatment of COVID-19 in light of the most recent evidence.

Early anakinra treatment may reduce the risk for poor outcomes in patients with COVID-19 who are at risk for progressing to respiratory failure on the basis of elevated soluble urokinase plasminogen activator receptor levels, SAVE-MORE trial data show.

Treatment with the IL-1 receptor antagonist anakinra may reduce mortality risk versus standard care in people with moderate-to-severe COVID-19, particularly those with hyperinflammation, suggests a systematic review and patient-level meta-analysis.

Click through for more information on this update

Treatment with the IL-1β inhibitor canakinumab does not improve the likelihood of survival without invasive mechanical ventilation among hospitalized patients with severe COVID-19 and systemic hyperinflammation, suggest findings from the CAN-COVID trial.

Rheumatoid arthritis and COVID-19 pneumonitis share some common pathogenic pathways that could be targeted in the development of treatment strategies for COVID-19, researchers report.

Treatment with IL-6 receptor antagonists is associated with a reduction in 28-day mortality risk among hospitalized patients with COVID-19, suggest findings from a meta-analysis published in JAMA .

Add-on treatment with the JAK inhibitor tofacitinib reduces the risk for death or respiratory failure among hospitalized patients with COVID-19 pneumonia who are not receiving mechanical ventilation, shows the STOP-COVID trial.